Corticosteroid therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials.

Published on May 21, 2021in Medicine1.552
· DOI :10.1097/MD.0000000000025719
Yashwitha Sai Pulakurthi2
Estimated H-index: 2
(Academy of Medical Sciences, United Kingdom),
John M. Pederson2
Estimated H-index: 2
+ 23 AuthorsKirk W. Evanson1
Estimated H-index: 1
Sources
Abstract
BACKGROUND Corticosteroid treatment is an effective and common therapeutic strategy for various inflammatory lung pathologies and may be an effective treatment for coronavirus disease 2019 (COVID-19). The purpose of this systematic review and meta-analysis of current literature was to investigate the clinical outcomes associated with corticosteroid treatment of COVID-19. METHODS We systematically searched PubMed, medRxiv, Web of Science, and Scopus databases through March 10, 2021 to identify randomized controlled trials (RCTs) that evaluated the effects of corticosteroid therapies for COVID-19 treatment. Outcomes of interest were mortality, need for mechanical ventilation, serious adverse events (SAEs), and superinfection. RESULTS A total of 7737 patients from 8 RCTs were included in the quantitative meta-analysis, of which 2795 (36.1%) patients received corticosteroids plus standard of care (SOC) while 4942 (63.9%) patients received placebo and/or SOC alone. The odds of mortality were significantly lower in patients that received corticosteroids as compared to SOC (odds ratio [OR] = 0.85 [95% CI: 0.76; 0.95], P = .003). Corticosteroid treatment reduced the odds of a need for mechanical ventilation as compared to SOC (OR = 0.76 [95% CI: 0.59; 0.97], P = .030). There was no significant difference between the corticosteroid and SOC groups with regards to SAEs and superinfections. CONCLUSION Corticosteroid treatment can reduce the odds for mortality and the need for mechanical ventilation in severe COVID-19 patients.
References25
Newest
#2Maria Eduarda Leão Farias (FIOCRUZ: Oswaldo Cruz Foundation)H-Index: 2
Last. Spain Icrea. BarcelonaH-Index: 2
view all 32 authors...
BACKGROUND: Steroid use for COVID-19 is based on the possible role of these drugs in mitigating the inflammatory response, mainly in the lungs, triggered by SARS-CoV-2 This study aimed at evaluating at evaluating the efficacy of methylprednisolone (MP) among hospitalized patients with suspected COVID-19 METHODS: Parallel, double-blind, placebo-controlled, randomized, phase IIb clinical trial was performed with hospitalized patients aged ≥ 18 years with clinical, epidemiological and/or radiologic...
131 CitationsSource
#1Luis Corral-Gudino (University of Valladolid)H-Index: 11
#2Alberto BahamondeH-Index: 1
Last. José A. Riancho (UC: University of Cantabria)H-Index: 46
view all 17 authors...
PURPOSE: To determine whether a 6-day course of methylprednisolone (MP) improves outcome in patients with severe SARS-CoV­2 (Corona Virus Disease 2019 [COVID-19]). METHODS: The study was a multicentric open-label trial of COVID-19 patients who were aged ≥ 18 years, receiving oxygen without mechanical ventilation, and with evidence of systemic inflammatory response who were assigned to standard of care (SOC) or SOC plus intravenous MP (40 mg bid for 3 days followed by 20 mg bid for 3 days)....
23 CitationsSource
#1Xiao Tang (Capital Medical University)H-Index: 7
#2Ying Mei Feng (Capital Medical University)H-Index: 1
Last. Bing Sun (Capital Medical University)H-Index: 12
view all 20 authors...
BACKGROUND: There is still no clinical evidence available to support or to oppose corticosteroid treatment for coronavirus disease 2019 (COVID-19) pneumonia. OBJECTIVE: To investigate the efficacy and safety of corticosteroid given to the hospitalized patients with COVID-19 pneumonia. METHODS: This was a prospective, multicenter, single-blind, randomized control trial. Adult patients with COVID-19 pneumonia who were admitted to the general ward were randomly assigned to either receive methylpred...
16 CitationsSource
#2Derek C. Angus (University of Pittsburgh)H-Index: 128
#3Lennie P G Derde (UU: Utrecht University)H-Index: 21
Last. Anthony C. Gordon (Imperial College Healthcare)H-Index: 40
view all 56 authors...
Importance Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19...
281 CitationsSource
#1Pierre-François Dequin (François Rabelais University)H-Index: 24
#2N Heming (Université Paris-Saclay)H-Index: 4
Last. Amélie Le Gouge (French Institute of Health and Medical Research)H-Index: 14
view all 22 authors...
Importance Coronavirus disease 2019 (COVID-19) is associated with severe lung damage. Corticosteroids are a possible therapeutic option. Objective To determine the effect of hydrocortisone on treatment failure on day 21 in critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute respiratory failure. Design, Setting, and Participants Multicenter randomized double-blind sequential trial conducted in France, with interim analyses planned every 50...
178 CitationsSource
#1Bruno Martins Tomazini (USP: University of São Paulo)H-Index: 5
#2Israel Silva MaiaH-Index: 7
view all 34 authors...
Importance Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) is associated with substantial mortality and use of health care resources. Dexamethasone use might attenuate lung injury in these patients. Objective To determine whether intravenous dexamethasone increases the number of ventilator-free days among patients with COVID-19–associated ARDS. Design, Setting, and Participants Multicenter, randomized, open-label, clinical trial conducted in 41 intensive car...
397 CitationsSource
#2Peter HorbyH-Index: 67
#3Wei Shen LimH-Index: 37
Last. Martin J LandrayH-Index: 52
view all 26 authors...
BACKGROUND: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. METHODS: In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care...
3,610 CitationsSource
#1Shivraj Hariram Nile (ZJNU: Zhejiang Chinese Medical University)H-Index: 24
#2Arti Nile (ZJNU: Zhejiang Chinese Medical University)H-Index: 10
Last. Guoyin Kai (ZJNU: Zhejiang Chinese Medical University)H-Index: 38
view all 6 authors...
ABSTRACT The outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) responsible for coronavirus disease 2019 (COVID-19) has developed into a major health hazard across the globe. The rapid escalation of the COVID-19 and the considerable associated illness leading to death has transformed it into a critical global public health issue. The current clinical investigation in patients with COVID-19 has showed strong upregulation of cytokine and interferon production after ...
156 CitationsSource
We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG and IgM titers plateaued within 6 days after seroconversion. Serological testing may be helpful for the diagnosis of suspected patients with negative RT–PCR results and for the identification of asymptomatic infections. A cross-sect...
1,650 CitationsSource
#1Xi He (Guangzhou Medical University)H-Index: 6
#2Eric H. Y. Lau (HKU: University of Hong Kong)H-Index: 37
Last. Gabriel M. Leung (HKU: University of Hong Kong)H-Index: 96
view all 23 authors...
We report temporal patterns of viral shedding in 94 patients with laboratory-confirmed COVID-19 and modeled COVID-19 infectiousness profiles from a separate sample of 77 infector–infectee transmission pairs. We observed the highest viral load in throat swabs at the time of symptom onset, and inferred that infectiousness peaked on or before symptom onset. We estimated that 44% (95% confidence interval, 25–69%) of secondary cases were infected during the index cases’ presymptomatic stage, in setti...
2,576 CitationsSource
Cited By3
Newest
#1Mario Fernández-Ruiz (Complutense University of Madrid)H-Index: 33
SARS-CoV-2 infection (COVID-19) has profoundly impacted transplant activity in our country. As immunocompromised hosts with common comorbidities, kidney transplant (KT) recipients were expected to have higher mortality and risk of complications associated to COVID-19 compared to the overall population. The available experience at the beginning of the pandemic, however, was very limited. Since March 2020 our knowledge on the epidemiology, clinical features and management of post-transplant COVID-...
Source
#1Jiayuan Tu (NU: Nanjing University)
#2Xiaoqiao Mo (SJTU: Shanghai Jiao Tong University)
Last. Tian Xie (HUST: Huazhong University of Science and Technology)
view all 8 authors...
To assess the efficacy and safety of corticosteroids in COVID-19 patients compared with standard care or placebo.Electronic databases were searched to identify relevant studies. The mortality, adve...
Source
#1Gustavo G. Resende (UFMG: Universidade Federal de Minas Gerais)H-Index: 10
#2Ricardo da Cruz Lage (UFMG: Universidade Federal de Minas Gerais)H-Index: 3
Last. Isabella GomesH-Index: 2
view all 16 authors...
ABSTRACT null Background null Patients with severe COVID-19 seem to have a compromised antiviral response and hyperinflammation. Neutrophils are critical players in COVID-19 pathogenesis. IL-17A plays a major role in protection against extracellular pathogens and neutrophil attraction and activation. We hypothesized that secukinumab, an anti-IL17A monoclonal antibody, could mitigate the deleterious hyperinflammation in COVID-19. null Methods null BISHOP was an open-label, single-center, phase-II...
Source